• PDF / 169,460 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 35 Downloads / 184 Views

DOWNLOAD

REPORT

---

1 S

QTc interval prolongation: case report In a retrospective study consisting of 3737 patients conducted in France between 03 March 2020 and 27 April 2020, a patient [age and sex not stated] was described, who developed QTc interval prolongation during off-label treatment with azithromycin and hydroxychloroquine for coronavirus disease (COVID-19). The patient, who had been diagnosed with COVID-19, started receiving off-label treatment with oral hydroxychloroquine 200mg three times daily for 10 days and azithromycin 500mg on day 1, followed by 250mg daily for the next four days. Prior to starting the treatment, the patient underwent electrolyte analysis and an EKG with corrected QT measurement. During the treatment, the patient exhibited prolongation of QTc ≥500ms [durations of treatments to reaction onset not stated]. The patient’s azithromycin and hydroxychloroquine therapy was therefore discontinued [outcome not stated]. Lagier J-C, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. 803505218 Travel Medicine and Infectious Disease 36: 101791, Aug 2020. Available from: URL: http://doi.org/10.1016/j.tmaid.2020.101791

0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 3 Oct 2020 No. 1824